CO5261488A1 - Indolinonas sustituidas en posiscion 6, su preparacion y utilizacion como medicamentos - Google Patents
Indolinonas sustituidas en posiscion 6, su preparacion y utilizacion como medicamentosInfo
- Publication number
- CO5261488A1 CO5261488A1 CO00077925A CO00077925A CO5261488A1 CO 5261488 A1 CO5261488 A1 CO 5261488A1 CO 00077925 A CO00077925 A CO 00077925A CO 00077925 A CO00077925 A CO 00077925A CO 5261488 A1 CO5261488 A1 CO 5261488A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- group
- amino
- phenyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Indolinonas sustituidas en posición 6 de la fórmula general<EMI FILE="00077925_1" ID="1" IMF=JPEG >En la que X significa un átomo de oxígeno o azufre, R1 significa un átomo de hidrógeno o un radical de profármaco R2 significa un grupo carboxi, un grupo alcoxi C1-6 -carbonilo lineal o ramificado, un grupo cicloalcoxi C4-7-carbonilo o un grupo ariloxi-carbonilo, un grupo alcoxi C1-6-carbonilo lineal o ramificado que en la parte de alquilo está sustituido en posición terminal con un grupo fenilo, heteroarilo, carboxi-alcoxi C1-3-carbonilo, amino-carbonilo, alquil C1-3-amino-carbonilo o di-(alquil C1-3)-amino-carbonilo, un grupo alcoxi C2-6,-carbonilo lineal o ramificado que en la parte de alquilo está sustituido en posición terminal con un átomo de cloro o un grupo hidroxi, alcoxi C1-3, amino, alquil C1-3-amino o di-(alquil C1-3)-amino, un grupo amino-carbonilo o metilamino-carbonilo, un grupo etilamino-carbonilo, eventualmente sustituido en la posición 2 del grupo etilo con un grupo hidroxi o alcoxi C1-3 o, si R1, no representa ningún grupo aminosulfonil-fenilo oN-(alquil C1-5)-alquil C1-3-aminocarbonil-fenilo, significa también un grupo di-(alquil C1-2)-amino-carbonilo, R3 significa un átomo de hidrógeno, un grupo alquilo C1-6, cicloalquilo C3-7, trifluorometilo o heteroarilo, un grupo fenilo o naftilo, un grupo fenilo o naftilo mono-o di-sustituido con un átomo de flúor, cloro, bromo o yodo, o con un grupo trifluorometilo, alquilo C1-3 o alcoxi C1-3, realizándose en el caso de la disustitución que los sustituyentes pueden ser iguales o diferentes y que los grupos fenilo y naftilo sin sustituir, así los mono-y di-sus-tituidos, que precedentemente se han mencionado, pueden estar sustituidos adicionalmente con un grupo hidroxi, hidroxi-alquilo C1-3 o alcoxi C1-3. -alquilo C1-3, - 2 -con un grupo ciano, carboxi, carboxi-alquilo C1-3, alcoxi C1-3-carbonilo, amino-carbonilo, alquil C1-3-amino-carbonilo o di-(alquil C1-3)amino-carbonilo,con un grupo nitro, con un grupo amino, alquil C1-3-amino, di-(alquil C1-3)-amino o amino-alquilo C1-3, con un grupo alquil C1-3-carbonil-amino, N-(alquil C1-3)-alquil C1-3-carbonil-amino, alquil C1-3 carbonil amino-alquilo C1-3, N-(alquil C1-3)-alquil C1-3-carbonil-amino-alquilo C1-3, alquil C1-3-sulfonil-amino, alquil C1-3-sulfonil-amino-alquilo C1-3, N-(alquil C1-3)-alquil C1-3-sulfonil-amino-alquilo C1-3 o aril-alquil C1-3-sulfonil-amino, con un grupo cicloalquil-amino, cicloalquilen-imino, cicloalquilen-imino-carbonilo, cicloalquilen-imino alquilo C1-3, cicloalquilen-imino-carbonil-alquilo C1-3 o cicloalquilen-imino-sulfonil-alquilo C1-3 en cada caso con 4 a 7 miembros de anillo, realizándose en cada caso que el grupo metileno situado en posición 4 en un grupo cicloalquilen-imino de 6 ó 7 miembros puede estar reemplazado por un átomo de oxígeno o azufre, o por un grupo sulfinilo, sulfonilo, -NH o -N(alquilo C1-3), o con un grupo heteroarilo o heteroaril-alquilo C1-3, R4 significa un grupo cicloalquilo C3-7, realizándose que el grupo metileno situado en posición 4 de un grupo cicloalquilo de 6 ó 7 miembros puede estar sustituido con un grupo amino, alquil C1-3-amino o di--(alquil C1-3)-amino, o puede estar reemplazado por un grupo -NH o -N(alquilo C1-3), o significa un grupo fenilo sustituido con el grupo R6, que puede estar adicionalmente mono-o di-sustituido con átomos de flúor, cloro, bromo o yodo, con grupos alquilo C1-5, tri-fluorometilo, hidroxi, alcoxi C1-3, carboxi, alcoxi C1-3-carbonilo, amino, acetil-amino, alquil C1-3-sulfonil-amino, amino-carbonilo, alquil C1-3 -amino-carbonilo, di-(alquil C1-3)-amino-carbonilo, aminosulfonilo, alquil C1-3-amino-sul-fonilo, di-(alquil C1-3)amino-sulfonilo, nitro o ciano, pudiendo los sustituyentes ser iguales o diferentes y significando R6 un átomo de hidrógeno, flúor, cloro, bromo o yodo, un grupo ciano, nitro, amino, alquilo C1-5, cicloalquilo C3-7, trifluorometilo, fenilo, tetrazolilo o heteroarilo el grupo de la fórmula <EMI FILE="00077925_2" ID="2" IMF=JPEG >en el que los átomos de hidrógeno unidos a un átomo de nitrógeno pueden estar reemplazados, en cada caso independientemente uno de otro, por un grupo alquilo C1-3, un grupo alcoxi C1-3, un grupo alcoxi C1-3-alcoxi C1-3, fenil- alcoxi C1-3, amino-alcoxi C2-3, alquil C1-3-amino-alcoxi C2-3, di-(alquil C1-3)amino-alcoxi C2-3, fenil-alquil C1-3-amino-alcoxi C2-3, N-(alquil C1-3)-fenil-alquil C1-3-amino-alcoxi C2-3, cicloalquilen C5-7 -imino-alcoxi C2-3 o alquil C1-3 mercapto, un grupo carboxi, alcoxi C1-4-carbonilo, amino-carbonilo, alquil C1-3 amino-carbonilo, N-(alquil C1-5)-alquil C1-3-amino-carbonilo, fenil-alquil C1-3-amino-carbonilo, N-(alquil C1-3)-fenil-alquil C1-3-amino-carbonilo, piperazino-carbonilo o N--(alquil C1-3)-piperazino-carbonilo, un grupo alquil C1-3-amino-carbonilo o N-(alquil C1-5)alquil C1-3-amino-carbonilo, en los que una parte de alquilo está sustituida con un grupo carboxi o alcoxi C1-3-carbonilo o, en posición 2 ó 3, con un grupo di(alquil C1-3)-amino, piperazino, N-(alquil C1-3)-piperazino o un grupo cicloalquilen-imino de 4 a 7 miembros, un grupo cicloalquil C3-7-carbonilo, realizándose que el grupo metileno situado en posición 4 de la parte de cicloalquilo de 6 ó 7 miembros puede estar sustituido con un grupo amino, alquil C1-3-amino o di-(alquil C1-3)-amino, o puede estar reemplazado por un grupo -NH o -N(alquilo C1-3), un grupo cicloalquilen-imino de 4 a 7 miembros, en el que un grupo metileno unido con el grupo imino puede estar reemplazado por un grupo carbonilo o sulfonilo o la parte de cicloalquileno puede estar condensada con un anillo de fenilo o uno o dos átomos de hidrógeno pueden estar reemplazados en cada caso, por un grupo alquilo C1-3 y/o a caso el grupo metileno en posición 4 de un grupo cicloalquilen-imino de 6 ó 7 miembros puede estar sustituido con un grupo carboxi, alcoxi C1-3 - carbonilo, amino-carbonilo, alquil C1-3-amino-carbonilo, di-(alquil C1-3)-amino-carbonilo, fenil-alquil C1-3-amino o N-(alquil C1-3)-fenil-alquil C1-3-amino o puede estar reemplazado por un átomo de oxígeno o azufre, por un grupo sulfinilo, sulfonilo, -NE, -N(alquilo C1-3), -N(fenilo), -N(alquil C1-3-carbonilo) o -N(benzoílo), un grupo alquilo C1-4 sustituido con el grupo R7, en donde R7 significa un grupo cicloalquilo C3-7, realizándose que el grupo metileno situado en posición 4 de un grupo cicloalquilo de 6 ó 7 miembros puede estar sustituido con un grupo amino, alquil C1-3-amino o di-(alquil C1-3)-amino, o puede estar reemplazado por un grupo -NH o -N(alquilo C1-3), en un grupo cicloalquilo de 5 a 7 miembros un grupo -(CH2)2 puede estar reemplazado por un grupo CONH, - 3 -un grupo -(CH2)3 puede estar reemplazado por un grupo -NH-CO-NH o -CO-NH-CO, o un grupo -(CH2)4 puede estar reemplazado por un grupo -NH- -CO-NH-CO, pudiendo en cada caso un átomo de hidrógeno unido a un átomo de nitrógeno estar reemplazado por un grupo alquilo C1-3, por un grupo arilo o heteroarilo, por un grupo hidroxi o alcoxi C1-3, por un grupo amino, alquil C1-7 -amino, di-(alquil C1-7)- -amino, fenilamino, N-fenil-alquil C1-3-amino, fenil alquil C1-3-amino, N-(alquil C1-3)-fenil-alquil C1-3-amino o di-(fenil-alquil C1-3)amino, por un grupo ù-hidroxi-alquil C2-3-amino, N-(alquil C1-3)--ù-hidroxi-alquil C2-3-amino, di-(ù-hidroxi-alquil C2-3- -amino, di-(ú-(alcoxi C1-3)-alquil C2-3)-amino o N-(dioxo-lan-2-il)-alquil C1-3-amino,por un grupo alquil C1-3-carbonil-amino-alquil C2-3-amino o alquil C1-3-carbonil-amino-alquil C2-3-N-(alquil C2-3)- -amino, por un grupo alquil C1-3-sulfonil-amino, N-(alquil C1-3)-alquil C1-3-sulfonil-amino, alquil C1-3-sulfonil-amino- -alquil C2-3-amino o alquil C1-3-sulfonil-amino-alquil C2-3 -N-(alquil C1-3)-amino, por un grupo hidroxicarbonil-alquil C1-3-amino o N-(alquil C1-3)-hidroxicarbonil-alquil C1-3-amino, por un grupo guanidino, en el que uno o dos átomos de hidrógeno pueden estar reemplazados en cada caso por un grupo alquilo C1-3, por un grupo de la fórmula -N(R8)-CO-(CH2)n-R9 (II), en la que R8 significa un átomo de hidrógeno o un grupo alquilo C1-3, n significa uno de los números 0, 1, 2 ó 3 y R9 significa un grupo arnino, alquil C1-4-amino, di- -(alquil C1-4)-amino, fenilamino, N-(alquil C1-4)-fenilamino, bencilamino, N-(alquil C1-4)bencilamino o alcoxi C1-4, un grupo cicloalquilen-imino de 4 a 7 miembros, realizándose que el grupo metileno situado en posición 4 de un grupo cicloalquilen- imino de 6 ó 7 miembros puede estar reemplazado por un átomo de oxígeno o azufre, por un grupo sulfinilo, sulfonilo, NH, -N(alquilo C1-3), -N(fenilo), -N(alquil C1-3-carbonilo) o -N(benzoílo) o, si n representa uno de los números 1, 2 ó 3, significa también un átomo de hidrógeno, por un grupo de la fórmula -N(R10)-(CH2)m-(CO)o-R11 (III), en la que R10 significa un átomo de hidrógeno, un grupo alquilo C1-3, un grupo alquil C1-3-carbonilo, aril-carbonilo, fenil-alquil C1-3-carbonilo, alquil C1-3-sulfonilo, aril-sulfonilo o fenil-alquil C1-3-sulfonilo, m significa uno de los números 1, 2, 3 ó 4, o significa el número 1 o, si m es uno de los números 2, 3 ó 4, significa también el número 0 y R11 significa un grupo amino, alquil C1-4-amino, di- -(alquil C1-4)amino, fenilamino, N-(alquil C1-4)-fenilamino, bencilamino, N-(alquil C1-4)bencilamino, alcoxi C1-4 o alcoxi C1-3-alcoxi C1-3, un grupo di-(alquil C1-4)-amino-alquil C1-3-amino, eventualmente sustituido en la posición 1 con un grupo alquilo C1-3, o un grupo cicloalquilen-imino de 4 a 7 miembros, realizándose que la parte de cicloalquileno puede estar condensada con un anillo de fenilo o en cada caso el grupo metileno situado en posición 4 de un grupo cicloalquilen-imino de 6 ó 7 miembros puede estar reemplazado por un átomo de oxígeno o azufre, por un grupo sulfinilo, sulfonilo, -NH, -N(alquilo C1-3), -N(fenilo), -N(alquil C1-3-carbonilo) o -N(benzoílo), por un grupo cicloalquil C4-7-amino, cicloalquil C4-7-alquil C1-3-amino o cicloalquenil C4-7-amino, en el que la posición 1 del anillo no parti
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19949208A DE19949208A1 (de) | 1999-10-13 | 1999-10-13 | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE2000142696 DE10042696A1 (de) | 2000-08-31 | 2000-08-31 | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261488A1 true CO5261488A1 (es) | 2003-03-31 |
Family
ID=26006858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00077925A CO5261488A1 (es) | 1999-10-13 | 2000-10-12 | Indolinonas sustituidas en posiscion 6, su preparacion y utilizacion como medicamentos |
Country Status (42)
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
US6638965B2 (en) | 2000-11-01 | 2003-10-28 | Boehringer Ingelheim Pharma Kg | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
US7700610B2 (en) | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
ATE376182T1 (de) | 2001-06-29 | 2007-11-15 | Ab Science | C-kit inhibitoren |
JP2004537537A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
US7678805B2 (en) | 2001-06-29 | 2010-03-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD) |
JP2004536097A (ja) * | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
US6765012B2 (en) * | 2001-09-27 | 2004-07-20 | Allergan, Inc. | 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
CN1290844C (zh) | 2001-12-27 | 2006-12-20 | 施万制药 | 用作蛋白激酶抑制剂的二氢吲哚酮衍生物 |
SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
ITBO20020198A1 (it) * | 2002-04-12 | 2003-10-13 | Univ Bologna | Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed |
US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
US20040204458A1 (en) | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
US7148249B2 (en) * | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
JP4879492B2 (ja) * | 2002-11-27 | 2012-02-22 | アラーガン、インコーポレイテッド | 疾患の治療のためのキナーゼ阻害剤 |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
SE0401790D0 (sv) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
WO2007057397A1 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
EP2036557B1 (en) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
EP1870400A1 (en) * | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
JP5319306B2 (ja) | 2007-01-29 | 2013-10-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌治療用組成物 |
WO2008152013A1 (en) * | 2007-06-12 | 2008-12-18 | Boehringer Ingelheim International Gmbh | Indolinone derivatives and their use in treating disease-states such as cancer |
DK2170827T3 (da) | 2007-06-21 | 2013-11-18 | Janssen Pharmaceutica Nv | Indolin-2-oner og aza-indolin-2-oner |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
RU2525114C2 (ru) * | 2007-12-03 | 2014-08-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения производного индолинона |
UY31506A1 (es) * | 2007-12-03 | 2009-08-03 | Derivados de indolinona y procedimiento para su preparacion | |
KR101760657B1 (ko) | 2008-06-06 | 2017-07-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 병용물 |
US8853420B2 (en) | 2008-07-29 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds |
US20120157472A1 (en) | 2009-01-14 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
JP2012526766A (ja) | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍性及び線維性疾患の処置における新規な併用療法 |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
WO2012068441A2 (en) | 2010-11-19 | 2012-05-24 | Ratiopharm Gmbh | Intedanib salts and solid state forms thereof |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
JP6152389B2 (ja) | 2012-01-26 | 2017-06-21 | アンジオン バイオメディカ コーポレーション | 抗線維化化合物及びその使用 |
WO2014071358A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
CN104936944B (zh) | 2012-12-06 | 2017-09-12 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
CN104003925B (zh) * | 2013-06-05 | 2016-03-30 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
WO2015009889A1 (en) * | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
CN104262232B (zh) * | 2014-09-09 | 2016-05-04 | 苏州明锐医药科技有限公司 | 尼泰达尼的制备方法 |
CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
WO2016178064A1 (en) | 2015-05-06 | 2016-11-10 | Suven Life Sciences Limited | Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof |
CN104844499B (zh) * | 2015-06-05 | 2017-03-08 | 北京康立生医药技术开发有限公司 | 一锅法制备尼达尼布的合成方法 |
CN114010787A (zh) * | 2015-06-06 | 2022-02-08 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
CN105126909B (zh) * | 2015-07-13 | 2018-01-23 | 淮海工学院 | 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用 |
CZ308695B6 (cs) | 2015-07-29 | 2021-03-03 | Zentiva, K.S. | Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu) |
CN106467500A (zh) * | 2015-08-14 | 2017-03-01 | 廊坊百瑞化工有限公司 | 一种一锅煮法合成尼达尼布关键中间体的新方法 |
EP3394048B1 (en) | 2015-12-24 | 2020-03-11 | Respivert Limited | Indolinones compounds and their use in the treatment of fibrotic diseases |
CZ2016104A3 (cs) | 2016-02-24 | 2017-09-06 | Zentiva, K.S. | Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy |
AU2017231860C1 (en) | 2016-03-08 | 2022-01-20 | Respivert Limited | Indole derivatives and their use as protein kinase inhibitors |
JP2019511547A (ja) | 2016-04-13 | 2019-04-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ |
EP3246029A1 (en) | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
US20190275032A1 (en) | 2016-05-27 | 2019-09-12 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone |
JP2019523225A (ja) | 2016-06-01 | 2019-08-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ニンテダニブおよびピルフェニドンによる治療開始を決定するためのecmバイオマーカーの使用 |
MX2018014868A (es) | 2016-06-02 | 2019-09-13 | Cloudbreak Therapeutics Llc | Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. |
EP3490553A4 (en) | 2016-07-29 | 2020-03-25 | Oncternal Therapeutics, Inc. | USE OF INDOLINON COMPOUNDS |
CN106748961A (zh) * | 2016-11-30 | 2017-05-31 | 瑞阳制药有限公司 | 尼达尼布的杂质化合物、制备方法、应用及其检测方法 |
CN106748960A (zh) * | 2016-11-30 | 2017-05-31 | 瑞阳制药有限公司 | 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法 |
WO2018108669A1 (en) | 2016-12-12 | 2018-06-21 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol |
WO2018177893A1 (en) | 2017-03-28 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of muscular dystrophy |
AU2018357775B2 (en) | 2017-10-23 | 2024-02-15 | Boehringer Ingelheim International Gmbh | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) |
JP7382317B2 (ja) | 2017-11-17 | 2023-11-16 | フェルミオン オサケ ユキチュア | ニンテダニブを製造するための中間体として公知の2-インドリノン誘導体の合成 |
JP7061310B2 (ja) * | 2018-04-05 | 2022-04-28 | 国立大学法人 大分大学 | 慢性脂肪性疾患の予防および治療用医薬 |
CN108358827A (zh) * | 2018-05-07 | 2018-08-03 | 日照市普达医药科技有限公司 | 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法 |
US20230009626A1 (en) * | 2018-10-05 | 2023-01-12 | Ichnos Sciences S.A. | Indolinone compounds for use as map4k1 inhibitors |
WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
CN111848490B (zh) * | 2020-08-24 | 2021-09-24 | 江西国药有限责任公司 | 一种高纯度乙磺酸尼达尼布的制备方法 |
CN112574094B (zh) * | 2020-12-14 | 2022-07-01 | 成都大学 | 吲哚酮衍生物及其制药用途 |
CN116981683A (zh) | 2021-01-25 | 2023-10-31 | 纳米智能生物医学工程有限公司 | 用于预防和治疗纤维化的肽 |
EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
CN115703758B (zh) * | 2021-08-12 | 2024-03-26 | 中国医学科学院药物研究所 | 一类用作激酶抑制剂的化合物及其制备方法和用途 |
WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE558210A (es) * | 1956-06-08 | |||
CA2166722A1 (en) * | 1994-05-06 | 1995-11-16 | Manoj L. Maniar | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
ATE243034T1 (de) * | 1996-01-17 | 2003-07-15 | Taiho Pharmaceutical Co Ltd | Intimale verdickungsinhibitoren |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
DE19815020A1 (de) * | 1998-04-03 | 1999-10-07 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19824922A1 (de) | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
-
2000
- 2000-09-10 UA UA2002053890A patent/UA75054C2/uk unknown
- 2000-10-09 ME MEP-454/08A patent/MEP45408A/xx unknown
- 2000-10-09 CZ CZ20021410A patent/CZ301073B6/cs unknown
- 2000-10-09 DK DK00971347.0T patent/DK1224170T5/en active
- 2000-10-09 BR BRPI0014735 patent/BRPI0014735B8/pt active IP Right Grant
- 2000-10-09 CA CA002387013A patent/CA2387013C/en not_active Expired - Lifetime
- 2000-10-09 IL IL14875600A patent/IL148756A0/xx active IP Right Grant
- 2000-10-09 SI SI200031039T patent/SI1224170T1/sl unknown
- 2000-10-09 EP EP09164507A patent/EP2157081A1/de not_active Withdrawn
- 2000-10-09 EP EP00971347.0A patent/EP1224170B9/de not_active Expired - Lifetime
- 2000-10-09 EE EEP200200197A patent/EE05427B1/xx active Protection Beyond IP Right Term
- 2000-10-09 RS YUP-266/02A patent/RS51013B/sr unknown
- 2000-10-09 AT AT00971347T patent/ATE439342T1/de active
- 2000-10-09 PT PT00971347T patent/PT1224170E/pt unknown
- 2000-10-09 KR KR1020027004701A patent/KR100835546B1/ko active IP Right Grant
- 2000-10-09 DE DE50015711T patent/DE50015711D1/de not_active Expired - Lifetime
- 2000-10-09 HU HU0204587A patent/HU230416B1/hu active Protection Beyond IP Right Term
- 2000-10-09 WO PCT/EP2000/009867 patent/WO2001027081A1/de active IP Right Grant
- 2000-10-09 SK SK646-2002A patent/SK287312B6/sk not_active IP Right Cessation
- 2000-10-09 PL PL355433A patent/PL207445B1/pl not_active IP Right Cessation
- 2000-10-09 ES ES00971347T patent/ES2331459T3/es not_active Expired - Lifetime
- 2000-10-09 MX MXPA02002799A patent/MXPA02002799A/es active IP Right Grant
- 2000-10-09 JP JP2001530102A patent/JP4021664B2/ja not_active Expired - Lifetime
- 2000-10-09 KR KR1020077017807A patent/KR100857734B1/ko active IP Right Grant
- 2000-10-09 EA EA200200380A patent/EA006080B1/ru not_active IP Right Cessation
- 2000-10-09 NZ NZ518489A patent/NZ518489A/en not_active IP Right Cessation
- 2000-10-09 CN CNB008158681A patent/CN100455568C/zh not_active Expired - Lifetime
- 2000-10-09 AU AU10233/01A patent/AU781939B2/en active Active
- 2000-10-11 MY MYPI20004762A patent/MY127956A/en unknown
- 2000-10-11 EG EG2000101293A patent/EG25931A/xx active
- 2000-10-11 PE PE2000001088A patent/PE20010671A1/es not_active IP Right Cessation
- 2000-10-12 CO CO00077925A patent/CO5261488A1/es not_active Application Discontinuation
- 2000-10-12 TW TW089121320A patent/TWI268922B/zh active
- 2000-10-13 AR ARP000105394A patent/AR026036A1/es active Pending
-
2001
- 2001-02-06 SA SA01210704A patent/SA01210704B1/ar unknown
-
2002
- 2002-03-19 IL IL148756A patent/IL148756A/en active Protection Beyond IP Right Term
- 2002-04-05 BG BG106587A patent/BG65983B1/bg active Active
- 2002-04-10 HR HR20020306A patent/HRP20020306B1/xx not_active IP Right Cessation
- 2002-04-11 NO NO20021719A patent/NO322746B1/no active Protection Beyond IP Right Term
-
2003
- 2003-06-30 HK HK03104649.4A patent/HK1052505B/zh not_active IP Right Cessation
-
2007
- 2007-08-15 JP JP2007211755A patent/JP2007302697A/ja active Pending
-
2009
- 2009-11-06 CY CY20091101152T patent/CY1110067T1/el unknown
-
2015
- 2015-03-13 CY CY2015009C patent/CY2015009I1/el unknown
- 2015-03-16 FR FR15C0024C patent/FR15C0024I2/fr active Active
- 2015-03-16 LU LU92681C patent/LU92681I2/xx unknown
- 2015-03-16 BE BE2015C018C patent/BE2015C018I2/fr unknown
- 2015-03-16 NL NL300725C patent/NL300725I2/nl unknown
- 2015-03-18 NO NO2015009C patent/NO2015009I1/no unknown
-
2016
- 2016-05-13 HU HUS1600022C patent/HUS1600022I1/hu unknown
-
2023
- 2023-09-05 NO NO2023033C patent/NO2023033I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261488A1 (es) | Indolinonas sustituidas en posiscion 6, su preparacion y utilizacion como medicamentos | |
FR16C0031I2 (fr) | S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih | |
AR052177A1 (es) | Medicamentos para el tratamiento o la prevencion de enfermedades fibroticas | |
CY1108403T1 (el) | Κυκλικης αμινης ενωση ως ανταγωνιστης ccr5 | |
UY26957A1 (es) | Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación | |
AR049393A1 (es) | Derivados fluoroglicosidicos de pirazoles con actividad inhibitoria de sglt 1; medicamentos que contienen estos compuestos y el empleo de los mismos en el tratamiento de la diabetes tipo i y tipo ii. | |
AR072471A1 (es) | BENZOXACINAS Y BENZOTIACINAS CON ACTIVIDAD INHIBIDORA DE NOS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO EN EL TRATAMIENTO DEL DOLOR. | |
ATE442364T1 (de) | Kristalline form von linezolid | |
IS7220A (is) | Latar af þætti XA og öðrum rað-próteösum sem tengjast storknunar keðjuverkun | |
CY1107851T1 (el) | Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2 | |
DK1841423T3 (da) | Anvendelse af 1-benzyl-1-hydroxy-2,3-diamino-propylaminer, 3-benzyl-3-hydroxy-2-aminopropionsyre-amider og beslægtede forbindelser som analgetika | |
HUP0301555A2 (hu) | Szubsztituált szulfonilaminometilbenzoesav-származékok és eljárás előállításukra | |
CY1109711T1 (el) | Νεα κρυσταλλικη μορφη υδροχλωριουχου λερκανιδιπινης και διαδικασιες για την παρασκευη τους | |
LU90975I2 (fr) | Sulfonamide sa préparation et son usage comme médicament et intermédiaire | |
BR0313747A (pt) | Inibidores de transcriptase reversa de não-nucleosìdeo | |
AR074822A1 (es) | Compuestos heterociclicos de pirazina utiles como inhibidores de proteinquinasas atr, composiciones farmaceuticas que los comprenden y uso de los mismos en el tratamiento del cancer | |
CY1105847T1 (el) | Γραμμικες βασικες ενωσεις που εμφανιζουν δραστικοτητα ανταγωνιστη της nk-2 και σκευασματα αυτων | |
ES2061463T3 (es) | Compuestos de piperidina y su preparacion y uso. | |
AR018199A1 (es) | 2-quinolinas nh- u o-sustituidas, procedimiento para su preparacion, una composicion farmaceutica que los comprende y el uso de las mismas para lafabricacion de un medicamento | |
UY29979A1 (es) | Derivados espirociclicos | |
ATE438626T1 (de) | 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze | |
AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
UY27424A1 (es) | Agentes antidiabéticos | |
EA200701692A1 (ru) | Ингибиторы протеазы вич | |
CO5261507A1 (es) | Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |